Calmare Therapeutics Discusses Complaint Settlement

Contract Negotiations Progressing at the Suggestion of the Court

FAIRFIELD, Conn.--(BUSINESS WIRE)--Calmare Therapeutics Incorporated (OTCQB:CTTC) (CTI), the Calmare^® pain mitigation company, discusses settlement with GEO-MC, Ltd. The disagreement dates back to the third quarter of 2014.

“Our flagship medical device, the Calmare® Pain Therapy Device, improves the quality of life of chronic neuropathic pain patients’ like no other modality on the market today”

“Our flagship medical device, the Calmare^® Pain Therapy Device, improves the quality of life of chronic neuropathic pain patients’ like no other modality on the market today,” said Calmare Therapeutics President and CEO Conrad Mir. “Legal matters and similar distractions take away from the greater good Calmare Pain Mitigation Therapy™ can bring. We need to turn the page on this matter and get back to what Calmare Therapeutics does best – give chronic pain patients their life back. They deserve our unconditional commitment to this resolution if not more.”

Calmare Pain Mitigation Therapy™

Calmare Pain Mitigation Therapy™ (PMT) has successfully improved the quality of life of chronic neuropathic pain patients across the globe without need of invasive treatments or prescription drugs. Calmare PMT offers comprehensive prolonged pain mitigation for 3 to 4 months. And, in those patients that are true responders patients may have full pain elimination that may last up to a year or more.

About the Company

Calmare Therapeutics Incorporated, the Calmare Pain Mitigation Therapy™ company, researches, develops and commercializes its flagship medical device – the non-invasive and non-addictive Calmare^® Pain Therapy Device. The Company holds the U.S. Food & Drug Administration 510k clearance on its Device, which grants it the exclusive right to sell, market, research and develop the medical device. Calmare Devices are commercially sold to medical practices throughout the world. They are also found in U.S. military hospitals, clinics and installations via CTI’s General Services Administration (GSA) military contract (V797P-4300B).

Forward-Looking Statement

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

www.calmaretherapeutics.com